ArticleCancer biology & medicine2016

Second-line panitumumab as a triweekly dose for patients with wild-type KRAS exon 2 metastatic colorectal cancer: a single-institution experience.

Mohamed A Daoud et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.